2. Rexahn Pharmaceuticals (RNN)
Company Profile: Rexahn Pharmaceuticals is a clinical-stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system to patients worldwide.
Altman Z-score: 69Closing Price: $1.24 (Sept. 15) Financial Metrics: Rexahn Pharmaceuticals has a price-to-book ratio of 6.25, which suggests the stock may be overvalued based on book value. Rexahn's quick ratio, which measures the ability to meet short-term obligations with its most liquid assets, is 11, indicating the biopharmaceutical company would be able to meet its current liabilities. Analyst Consensus: No research firm has coverage on Rexahn, although one had a "buy" rating on the stock about three months ago.